12
Participants
Start Date
February 4, 2020
Primary Completion Date
November 8, 2020
Study Completion Date
November 8, 2020
Tavapadon tablet
Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)
Tavapadon [14C] suspension
Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16
Covance Clinical Research Unit, Inc., Madison
Lead Sponsor
Cerevel Therapeutics, LLC
INDUSTRY